Novel therapeutic options for cachexia and sarcopenia

Expert Opinion on Biological Therapy

Volumn 16, Issue 10, 2016, Pages 1239-1244

  Molfino, Alessio ^a   Amabile, Maria Ida ^a   Rossi Fanelli, Filippo ^a   Muscaritoli, Maurizio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological therapies; cachexia; cancer; chronic diseases; metabolic and nutritional pathways; sarcopenia

Indexed keywords

ANAMORELIN; ANTIBODY; BIMAGRUMAB; CYTOKINE; ENOBOSARM; GHRELIN; INFLIXIMAB; MABP 1; MICRORNA; MYOSTATIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; ANDROGEN RECEPTOR; ANILIDE; AR PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

CACHEXIA; CENTRAL NERVOUS SYSTEM; DRUG EFFECT; DRUG TARGETING; HUMAN; INFLAMMATION; MUSCLE ATROPHY; MUSCLE METABOLISM; MUSCLE STRENGTH; NUTRITION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; REVIEW; SARCOPENIA; SKELETAL MUSCLE; AGONISTS; ANIMAL; DRUG EFFECTS; METABOLISM; QUALITY OF LIFE;

ANILIDES; ANIMALS; ANTIBODIES, MONOCLONAL; CACHEXIA; GHRELIN; HUMANS; MUSCLE, SKELETAL; QUALITY OF LIFE; RECEPTORS, ANDROGEN; SARCOPENIA;

EID: 84985952113     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1080/14712598.2016.1208168     Document Type: Review

References (47)

1. M.Muscaritoli, S.D.Anker, J.Argilés, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia:joint document elaborated by Special Interest Groups (SIG) ‘cachexia-anorexia in chronic wasting diseases’ and ‘nutrition in geriatrics’. Clin Nutr. 2010;29(2):154–159.•• Article provides working definition of pre-cachexia, cachexia, and sarcopenia.
2. K.Fearon, F.Strasser, S.D.Anker, et al. Definition and classification of cancer cachexia:an international consensus. Lancet Oncol. 2011;12(5):489–495.
3. J.Woo, J.Leung, J.E.Morley Validating the SARC-F:a suitable community screening tool for sarcopenia? J Am Med Dir Assoc. 2014;15:630–634.
4. D.R.Alchin. Sarcopenia:describing rather than defining a condition. J Cachexia Sarcopenia Muscle. 2014;5:265–268.
5. M.Muscaritoli, S.Lucia, A.Molfino, et al. Muscle atrophy in aging and chronic diseases:is it sarcopenia or cachexia? Intern Emerg Med. 2013;8(7):553–560.
6. C.Drescher, M.Konishi, N.Ebner, et al. Loss of muscle mass:current developments in cachexia and sarcopenia focused on biomarkers and treatment. J Cachexia Sarcopenia Muscle. 2015;6:303–311.
7. M.Muscaritoli, A.Molfino, S.Lucia, et al. Cachexia:a preventable comorbidity of cancer. A T.A.R.G.E.T. approach. Crit Rev Oncol Hemat. 2015;94:251–259.
8. T.R.Balstad, S.Kaasa, T.S.Solheim. Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care. 2014;17:226–235.
9. A.Molfino, A.Formiconi, F.Rossi Fanelli, et al. Cancer cachexia:towards integrated therapeutic interventions. Expert Opin Biol Ther. 2014;14(10):1379–1381.
10. S.von Haehling, S.D.Anker. Treatment of cachexia:an overview of recent developments. Int J Cardiol. 2015;184:736–742.
11. A.Molfino, M.I.Amabile, M.Monti, et al. Carnitine for the treatment of cachexia:lights and shadows. Int J Cardiol. 2015;198:180–181.
12. A.Maccio, C.Madeddu, G.Mantovani. Current pharmacotherapy options for cancer anorexia and cachexia. Expert Opin Pharmacother. 2012;13:2453–2472.
13. C.Pietra, Y.Takeda, N.Tazawa-Ogata, et al. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome:preclinical profile. J Cachexia Sarcopenia Muscle. 2014;5:329–337.
14. A.Molfino, G.Gioia, M.Muscaritoli. The hunger hormone ghrelin in cachexia. Expert Opin Biol Ther. 2013;13(4):465–468.
15. J.M.Garcia, R.V.Boccia, C.D.Graham, et al. Anamorelin for patients with cancer cachexia:an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16(1):108–116.
16. J.S.Temel, A.P.Abernethy, D.C.Currow, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2):results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531. doi:10.1016/S1470-2045(15)00558-6.•• Article describes the most recent findings on anamorelin in large clinical trials.
17. K.M.Heppner, J.Tong. Mechanisms in endocrinology:regulation of glucose metabolism by the ghrelin system:multiple players and multiple actions. Eur J Endocrinol. 2014;171(1):R21–32.
18. M.Muscaritoli. Targeting cancer cachexia:we’re on the way. Lancet Oncol. 2016;17:414–415. pii:S1470-2045(16)00085-1. doi:10.1016/S1470-2045(16)00085-1.
19. L.Martin, L.Birdsell, N.Macdonald, et al. Cancer cachexia in the age of obesity:skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31(12):1539–1547.
20. A.Molfino, A.Formiconi, F.Rossi Fanelli, et al. Ghrelin:from discovery to cancer cachexia therapy. Curr Opin Clin Nutr Metab Care. 2014;17(5):471–476.•• This article includes a large number of experimental and clinical evidences on the role of ghrelin in cachexia.
21. K.Koshinaka, K.Toshinai, A.Mohammad, et al. Therapeutic potential of ghrelin treatment for unloading-induced muscle atrophy in mice. Biochem Biophys Res Commun. 2011;412:296–301.
22. M.Llovera, N.Carbó, J.López-Soriano, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998;133(1):83–87.
23. V.Dutta, S.Guptaa, R.Daburb, et al. Skeletal muscle atrophy:potential therapeutic agents and their mechanisms of action. Pharmacol Res. 2015;99:86–100.
24. K.Subramaniam, K.Fallon, T.Ruut, et al. Infliximab reverses inflammatory muscle wasting (sarcopenia) in Crohn’s disease. Aliment Pharmacol Ther. 2015;41(5):419–428.
25. I.W.McKinnell, M.A.Rudnicki. Molecular mechanisms of muscle atrophy. Cell. 2004;119:907–910.
26. M.Tsoli, M.M.Swarbrick, G.R.Robertson. Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. Semin Cell Dev Biol. 2015. pii:S1084-9521(15)00246-3. doi:10.1016/j.semcdb.2015.10.039.
27. X.Yao, J.Huang, H.Zhong, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Ther. 2014;141:125–139.
28. K.Ando, F.Takahashi, M.Kato, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin 6-expressing lung cancer. PLoS One. 2014;9:e102436. doi:10.1371/journal.pone.0102436.
29. D.S.Hong, D.Hui, E.Bruera, et al. MABp1, a first-in-class true human antibody targeting IL-1a in refractory cancers:an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014;15:656e666.
30. Y.Elkina, S.von Haehling, S.D.Anker, et al. The role of myostatin in muscle wasting:an overview. J Cachexia Sarcopenia Muscle. 2011;2:143–151.
31. E.Lach-Trifilieff, G.C.Minetti, K.A.Sheppard, et al. An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy. Mol Cell Biol. 2014;34(4):606–618.
32. H.Q.Han, X.Zhou, W.E.Mitch, et al. Myostatin/activin pathway antagonism:molecular basis and therapeutic potential. Int J Biochem Cell Biol. 2013;45:2333–2347.
33. X.Zhou, J.L.Wang, J.Lu, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142:531–543.
34. A.A.Amato, K.Sivakumar, N.Goyal, et al. Treatment of sporadic inclusion body myositis with bimagrumab. Neurology. 2014;83:2239–2246.
35. C.Becker, S.R.Lord, S.A.Studenski, et al. Myostatin antibody (LY2495655) in older weak fallers:a proof-of-concept, randomised, phase 2 trial. Lancet Diabetes Endocrinol. 2015;3(12):948–957.
36. N.Ebner, J.Springer, K.Kalantar-Zadeh, et al. Mechanism and novel therapeutic approaches to wasting in chronic disease. Maturitas. 2013;75:199–206.
37. V.Dubois, M.Laurent, S.Boonen, et al. Androgens and skeletal muscle:cellular and molecular action mechanisms underlying the anabolic actions. Cell Mol Life Sci. 2012;69(10):1651–1667.
38. V.Dubois, I.Simitsidellis, M.R.Laurent, et al. Enobosarm (GTx-024) modulates adult skeletal muscle mass independently of the androgen receptor in the satellite cell lineage. Endocrinology. 2015;156:4522–4533.
39. A.S.Dobs, R.V.Boccia, C.C.Croot, et al. Effects of enobosarm on muscle wasting and physical function in patients with cancer:a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013;14:335–345.
40. R.Srinath, A.Dobs. Enobosarm (GTx-024, S-22):a potential treatment for cachexia. Future Oncol. 2014;10:187–194.
41. K.Fearon, J.M.Argiles, V.E.Baracos, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle. 2015;6:272–274.
42. L.Chen, D.R.Nelson, Y.Zhao, et al. Relationship between muscle mass and muscle strength, and the impact of comorbidities:a population-based, cross-sectional study of older adults in the United States. BMC Geriatr. 2013;13:74.
43. G.Biolo, T.Cederholm, M.Muscaritoli. Muscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases:from sarcopenic obesity to cachexia. Clin Nutr. 2014;33:737–748.
44. J.P.Michel, A.J.Cruz-Jentoft, T.Cederholm. Frailty, exercise and nutrition. Clin Geriatr Med. 2015;31:375–387.
45. T.J.Kirby, T.Chaillou, J.J.McCarthy. The role of microRNAs in skeletal muscle health and disease. Front Biosci (Landmark Ed). 2015;20:37–77.
46. B.Siddeek, L.Inoubli, N.Lakhdari, et al. MicroRNAs as potential biomarkers in diseases and toxicology. Mutat Res Genet Toxicol Environ Mutagen. 2014;764-765:46–57.
47. W.A.He, F.Calore, P.Londhe, et al. Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc Natl Acad Sci U S A. 2014;111(12):4525–4529.